Table 3.

Evaluation of response in osimertinib treatment patients according to T790M status by tag-based NGS

Patient	Sex	Age (yrs, median 71)	Sensitizing EGFR mut	osimertinib, response	plasma T790M
					Real Time PCR	tag-based NGS
24	M	58	exon 19 del	PR	pos	pos
27	F	74	L858R	PD	pos	pos
25	F	71	L858R	SD	neg	pos
14	F	75	exon 19 del	SD	neg	nega
35	M	64	exon 19 del	PR	neg	pos
26	F	66	L858R	PR	neg	pos
15	M	75	L858R	SD	neg	pos
2	M	71	exon 19 del	PR	neg	pos
18	F	72	exon 19 del	PR	pos	pos
6	M	78	exon 19 del	PR	pos	pos
10	F	71	exon 19 del	PR	pos	pos
36	F	85	exon 19 del	SD	pos	pos
37	F	65	exon 19 del	PR	pos	pos
39	M	75	G719C	PR	pos	pos
33	F	82	L858R	not evaluable	neg	pos
16	F	66	exon 19 del	SD	neg	pos
22	F	62	exon 20 ins	SD	neg	pos

del deletion, PR Partial Response, PD Progressive Disease, SD Stable Disease, pos positive, neg negative

^athis patient has been treated with third generation TKI because of T790M-positivity in post-TKI tissue